Survival markers related to bone metastases in prostate cancer

Anticancer Research

Volumn 26, Issue 6 C, 2006, Pages 4879-4884

  Salminen, E K ^a,b   Kallioinen, M J ^a   Ala Houhala, M A ^a   Vihinen, P P ^a   Tiitinen, S L ^a   Varpula, M ^a   Vahlberg, T J ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b NONE   (Finland)

Author keywords

Bone metastases; MMP; Prostate cancer; Survival; tALP; TRACP 5b

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5B; ALKALINE PHOSPHATASE; ANDROGEN; GELATINASE A; GELATINASE B; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANDROGEN THERAPY; AREA UNDER THE CURVE; ARTICLE; BONE METASTASIS; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER;

ACID PHOSPHATASE; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BONE NEOPLASMS; CROSS-SECTIONAL STUDIES; HUMANS; ISOENZYMES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 33845946547     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC and Michats MJ: Metabolic pattern of prostate cancer: an autopsy study of 1589 patients. Tumor Pathol 31: 578-583, 2000.
2. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee K, Zheng M, Hei Y-J and Coleman RE: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer and other solid tumours. JNCI 97: 59-69, 2005.
3. Green JR: Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphanates. Acta Oncologica 44: 282-292, 2005.
4. Janckila AJ, Takahashi K, Sun SZ and Yam LT: Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem 47: 74-80, 2001.
5. Hannon RA, Clowes JA, Eagleton AC, Al Hadari A, Eastell R and Blumsohn A: Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 34: 187-194, 2004.
6. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ and Vaananen HK: Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 15: 1337-1345, 2000.
7. Vihinen P and Kähäri VM: Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets. Int J Cancer 99: 157-166, 2002.
8. Zhang L, Shi J, Feng J, Klocker H, Lee C and Zhang J: Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis 7: 327-332, 2004.
9. DeLong ER, DeLong DM and Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44: 837-845, 1988.
10. Roodman GD: Mechanisms of bone metastasis. NEJM 350: 1655-1664, 2004.
11. Eastham JA: Active surveillance for prostate cancer with selective delayed definitive therapy. Clin Prostate Cancer 4: 45-49, 2005.
12. Scher HI and Chung LWK: Bone metastases: biology and therapy. Semin Oncol 21: 630-656, 1994.
13. Rubens, R. Bone metastases- the clinical problem. Eur J Cancer 34: 213, 1998.
14. Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB, Foley JP, Roffenburg RH and Moul JW: Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61: 607-611, 2003.
15. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid H-P, van Poppel H, Wolff J and Zatoni F: EAU guidelines on prostate cancer. European Urology 48: 546-551, 2005.
16. Salminen E, Hogg A, Binns D, Frydenberg M and Hicks R: FDG-PET has limited clinical value in the management of prostate cancer. Acta Oncol 41: 425-429, 2002.
17. Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R and Higano CS: Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23: 2918-2925, 2005.
18. Salminen EK, Ala-Houhala M, Korpela J, Varpula M, Alatalo SL, Halleen JM and Vaananen HK: Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer. Acta Oncol 44: 742-747, 2005.
19. Petrioli R, Rossi S, Caniggia M, Pozzere D, Messinese S, Sabatino M, Marsili S, Correale P, Salvestrini F, Manganelli A and Francini G: Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases. Urology 65: 321-326, 2004.
20. Jung K, Lein M, Stephan C, Von Hosslin K, Semjonow A, Sinha P, Loening SA and Schnorr D: Comparison of 10 serum bone tumour markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111: 783-791, 2004.
21. Ross JS, Kaur P, Sheehan CE, Fisher HA, Kaufman RA Jr and Kallakury BV: Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 16: 198-205, 2003.
22. Chan LW, Moses MA, Goley E, Sproull M, Muanza T, Coleman CN, Figg WD, Albert PS, Menard C and Camphausen K: Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol 22: 499-506, 2004.
23. Dong Z, Bonfil RD, Chinni S, Deng X, Trindade Filho JC, Bernardo M, Vaishampayan U, Che M, Sloane BF, Sheng S, Fridman R and Cher ML: Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol 166: 1173-1186, 2005.
24. Meisser A, Cohen M and Bischof P: Concentrations of circulating gelatinases (MMP 2 and -9) are dependent on the conditions of blood collection. Clin Chem 51: 274-276, 2005.
25. Royu D, Ernens I, Jeantly C and Wagner DR: Plasma storage at -80°C does not protect matrix metalloproteinases from degradation. Analytical Biochemistry 338: 294-298, 2005.